The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re‐induction therapy. Cytogenetic analysis performed at trial registration defined t(...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Cook, Gordon, Royle, Kara‐Louise, O'Connor, Sheila, Cairns, David A., Ashcroft, A. John, Williams, Cathy D., Hockaday, Anna, Cavenagh, Jamie D., Snowden, John A., Ademokun, Debo, Tholouli, Eleni, Andrews, Vivienne E., Jenner, Matthew, Parrish, Christopher, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M., Pratt, Guy, Drayson, Mark T., Brown, Julia M., Morris, Treen C. M.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Haematological Malignancy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6519200/
https://ncbi.nlm.nih.gov/pubmed/30729512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15782
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares